Phase III study of adjuvant ado trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE nal IDFS and updated OS analysis
HER2CLIMB-02: Randomized, double blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer
Key abstracts/publications in HER2+ve Breast Cancer
Chairpersons :
Dr. Shyam Agrawal, Dr. S D Banavali
Speaker :
Dr. Manuprasad Avaronnan